Available Trials

Breast |  Chemotherapy-Induced Nausea/Vomiting |  Colon |  Head and Neck |  Leukemia |  Lung |  Lymphoma |  Myelomas |  Prostate |  Solid Tumors |

Breast

  • NKTR-102 OR Physician’s Choice in Locally Recurrent or Metastatic Breast Cancer
    A Phase III Study of NKTR-102 versus Physician’s Choice in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, Taxane, and Capecitabine.

  • Eribulin +/- Remucirumab in Metastatic Breast Cancer
    A Phase II Study evaluating the efficacy and safety of Ramucirumab (IMC-1121B) in combination with Eribulin versus Eribulin monotherapy in unresectable, locally recurrent or metastatic breast cancer patients previously treated with Anthracycline and Taxane therapy.

  • Rd Letrozole± Dasatinib HR+ PostMen Met
    Randomized Phase II Trial of Letrozole with or without Dasatinib as First and Second-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic
  • D-CARE Adjuvant Denosumab BrCa
    A randomized, double-blind, placebo-controlled, multi-center Phase III study of Denosumab as adjuvant treatment for women with early-stage breast cancer at high risk of recurrence (D-CARE).

Chemotherapy-Induced Nausea/Vomiting

  • CINV Patient Reported Outcomes
    Phase II Study of Cetuximab +/- PX-866 for Patients with a Recurrence or Progression Following Irinotecan and Oxaliplatin Treatment.

Colon

  • PX-866 +/- Cetuximab
    Phase II Study of Cetuximab +/- PX-866 for Patients with a Recurrence or Progression Following Irinotecan and Oxaliplatin Treatment.

Head and Neck

  • PX-866 +/- Cetuximab
    Phase II Study of Cetuximab +/- PX-866 for Patients with a Recurrence or Progression Following at Least One Prior Platinum-Based Regimen or Chemotherapy/Radiation Containing Regimen.

  • PX-866 P13K +/- Docetaxel
    Phase II Study of Docetaxel +/- PX-866 for Patients who Have Received at Least One Prior Regimen for Locally Advanced, Recurrent, or Metastatic Head and Neck Cancer.

  • Cetux+Cis/Carbo/5FU H&N
    A Randomized, Double-Blind, Phase II Safety Study of Cetuximab, using ImClone versus Boehringer Ingelheim Manufacturing Processes, in Combination with Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients with Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Leukemia

Lung

  • GDC-0941/Carboplatin/Taxol or GDC0941/Carboplatin/Taxol/Avastin
    A Phase II Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Taxol and Carboplatin/Taxol/Avastin with and without GDC-0941 in Patients Previously Untreated Advanced or Recurrent NSCLC.

  • Ipilimumab or Placebo with Carboplatin/Taxol in Patients with Recurrent/Stage IV NSCLC
    A Phase III Randomized Study Comparing the Efficacy of Ipilimumab/Placebo in Addition to Taxol and Carboplatin in Patients with Stage IV/Recurrent
    NSCLC.

  • PX-866 P13K +/- Docetaxel
    Phase II Study of Docetaxel +/- PX-866 for Patients who have Received at Least One Prior Regimen for Advanced, Recurrent, or Metastatic NSCLC.

  • Docetaxel +/- 1121B 2nd Ln NSCLC
    A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression Aſter One Prior Platinum-Based Terapy.

  • IMC-1121B + Plat vs. Plat 1st Ln NSCLC
    An Open-Label, Multi-Center, Randomized, Phase II Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-Based Chemotherapy versus Platinum-Based Chemotherapy Alone as First-Line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Lymphoma

  • RAD001 Or Placebo in DLBCL
    A Double-Blind Placebo Controlled Phase III Study of RAD001 Adjuvant Terapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma versus Matching Placebo Aſter Patients Have Achieved Complete Response with First-Line Rituxan.

  • CHOP + GA101
    Phase II open label of the safety and efficacy of GA 101 in combination with CHOP chemotherapy in patients with previously untreated advanced Diffuse Large B-Cell Lymphoma
  • Pixantrone+Ritux vs Gem+Ritux RR NHL
    A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant


Myelomas

Prostate

Solid Tumors

  • ACE-011 Anemia in Select Solid Tumors
    An Open-Label Randomized, Phase IIA, DoseRanging Study (Part 1) of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects
    with Selected Metastatic Solid Tumors Treated with Platinum-Based Chemotherapeutic Regimens Followed by a Phase IIB/III, Double-Blind, Randomized, Placebo-Controlled Study (Part II) of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects with Metastatic Non-Small Cell Lung Cancer Treated with First-Line Platinum-Based Chemotherapeutic Regimens.

  • SGN-35 CD30+Non-Lymphoma Malignancies
    A Phase II, Open-Label, Single-Arm Study of Brentuximab Vedotin in Patients with CD30-Positive Nonlymphomatous Malignancies.